KRAS and lung cancer: To determine the in vivo relevance of our findings in both mutant KRAS AALE and HBEC cells, we examined ISG expression in mutant KRAS(G12D) lung adenocarcinomas (LUAD) from The Cancer Genome Atlas (TCGA), which revealed a subset of ISGs that were upregulated in KRAS(G12D) tumors when compared to lung cancer samples with wild-type (WT) KRAS (Figure 1E).